29 February 2024
NOT FOR RELEASE, PUBLICATION OR
DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN,
ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR
DISTRIBUTE THIS ANNOUNCEMENT. THIS ANNOUNCEMENT CONTAINS INSIDE
INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE
REGULATIONS (EU) NO. 596/2014 WHICH FORMS PART OF
DOMESTIC UK LAW PURSUANT TO THE
EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR").
MARKET SOUNDINGS WERE TAKEN IN
RESPECT OF THE MATTERS CONTAINED IN THIS ANNOUNCEMENT, WITH THE
RESULT THAT CERTAIN PERSONS BECAME AWARE OF SUCH INSIDE
INFORMATION. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE
INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH
PERSONS SHALL THEREFORE CEASE TO BE IN POSSESSION OF INSIDE
INFORMATION.
Hemogenyx
Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the
"Company")
Placing to Raise US$4.2 million
Hemogenyx Pharmaceuticals plc (LSE: HEMO),
the biopharmaceutical group developing new therapies and treatments
for blood diseases, is pleased to announce that it has
successfully raised US$4.2 million (£3.325 million) before
expenses through the allotment and issue of 166,250,000 new
ordinary shares at 2 pence per share (the "Placing", "Placing
Shares").
The net proceeds from the Placing
will be used to facilitate the development of the Company's
Chimeric Antigen Receptor T-cells ("HEMO-CAR-T")
for the treatment of acute myeloid leukaemia ("AML"). As announced on 9 February 2024, the Company was informed by
the U.S. Federal Food and Drug Administration ("FDA") that it had
lifted the clinical hold on the Investigational New Drug ("IND")
application for HEMO-CAR-T for the treatment of AML. The funds
have been raised to allow the Company to progress HEMO-CAR-T to
phase 1 clinical trials.
An application is being made to the
London Stock Exchange Main Market and admission of the Placing
Shares to trading is expected on or around 6 March 2024
("Admission"). The Placing Shares will rank pari passu with the existing
ordinary shares in the Company.
Dr Vladislav Sandler, CEO &
Co-Founder of Hemogenyx Pharmaceuticals,
commented:
"We are extremely pleased to have
raised these funds to allow us to progress our lead asset,
HEMO-CAR-T, to clinical trials. This is a key development that
represents the progression of Hemogenyx Pharmaceuticals to become a
clinical stage company and the fundraise was crucial to enable us
to progress toward clinical trials, the essential next step for the
development of HEMO-CAR-T. I would like to thank new and existing
shareholders for their support and for contributing to this
sizeable fundraise in difficult market conditions. The recent
lifting of the clinical hold by the FDA on our HEMO-CAR-T programme
followed a great effort from everyone at Hemogenyx Pharmaceuticals
for which I am very grateful."
Total Voting Rights
For the purpose of the Disclosure
Guidance and Transparency Rules, following Admission the enlarged
issued share capital of the Company will comprise 1,341,815,988
ordinary shares. The Company does not hold any shares in treasury.
The above figure may be used by shareholders as the denominator for
the calculations by which they will determine if they are required
to notify their interest in, or a change to their interest in, the
Company, under the Disclosure Guidance and Transparency
Rules.
For the purposes
of UK MAR, the person responsible for arranging for the
release of this Announcement on behalf of the Company is Dr
Vladislav Sandler, Chief Executive Officer &
Co-Founder.
Enquiries:
|
Hemogenyx Pharmaceuticals
plc
|
https://hemogenyx.com
|
|
Dr Vladislav Sandler, Chief
Executive Officer & Co-Founder
|
headquarters@hemogenyx.com
|
|
Peter Redmond, Director
|
peter.redmond@hemogenyx.com
|
|
SP Angel Corporate Finance
LLP
|
Tel: +44 (0)20 3470 0470
|
|
Matthew Johnson, Vadim Alexandre,
Adam Cowl
|
|
|
Peterhouse Capital
Limited
|
Tel: +44 (0)20 7469 0930
|
|
Lucy Williams, Duncan Vasey, Charles
Goodfellow
|
|
About Hemogenyx
Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a
publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries,
Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located
in New York City at its
state-of-the-art research facility.
The Company is a pre-clinical stage
biopharmaceutical group developing new medicines and treatments to
treat blood and autoimmune disease and to bring the curative power
of bone marrow transplantation to a greater number of patients
suffering from otherwise incurable life-threatening diseases.
Hemogenyx Pharmaceuticals is developing several distinct and
complementary product candidates, as well as platform technologies
that it uses as engines for novel product development.